Status:
COMPLETED
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Lead Sponsor:
UCB Pharma
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This is a Phase IIIb multicenter study to evaluate the safety and efficacy of certolizumab pegol (CZP) administered to patients with moderate-to-severe rheumatoid arthritis.
Detailed Description
The treatment period starts with a 12-week, double-blind, placebo-controlled, randomized period followed by an open-label extension phase. In the double-blind phase, eligible patients are randomized (...
Eligibility Criteria
Inclusion
- Adult patient with established moderate to severe rheumatoid arthritis
Exclusion
- All concomitant diseases or pathological conditions that could interfere and impact the assessment of the study treatment
- Previous clinical trials and previous biological therapy that could interfere with the results in the present clinical trials
Key Trial Info
Start Date :
July 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2011
Estimated Enrollment :
1648 Patients enrolled
Trial Details
Trial ID
NCT00717236
Start Date
July 1 2008
End Date
March 1 2011
Last Update
August 1 2018
Active Locations (181)
Enter a location and click search to find clinical trials sorted by distance.
1
Birmingham, Alabama, United States
2
Montgomery, Alabama, United States
3
Phoenix, Arizona, United States
4
Tucson, Arizona, United States